Categories
Change Password!
Reset Password!
Mepolizumab successfully reduces exacerbations and oral corticosteroid use while improving lung function and asthma control in children with severe eosinophilic asthma.
Children suffering from severe asthma may finally have a safer, more effective treatment option. A novel real-world study reveals that mepolizumab, an anti-interleukin (IL)-5 biologic, can transform the lives of children with severe eosinophilic asthma (SEA), improving lung function, controlling symptoms, and sharply reducing the need for oral corticosteroids (OCS).
Severe asthma in children is a complex ailment linked with frequent exacerbations, hampered lung function, and substantial healthcare costs. Traditional therapies often rely on high-dose inhaled corticosteroids (ICS) and systemic OCS, which carry the likelihood of long-term side effects. Biologic treatments, such as mepolizumab, target specific inflammatory pathways, including IL-5, offering a more targeted approach for those aged 6 years and older with SEA.
This retrospective study analyzed 33 pediatric patients (ages 6–17) across three tertiary centers in Turkiye. All patients met Global Initiative for Asthma (GINA) criteria for severe asthma, had experienced ≥2 severe exacerbations requiring OCS in the previous year, were on high-dose ICS plus a second controller, and had elevated eosinophil counts. The study assessed outcomes over 24 months, focusing on exacerbation rates, pulmonary function tests, OCS use, asthma control test (ACT) scores, blood eosinophil counts, and adverse events.
Key findings
Implications for pediatric asthma care
These results portray that mepolizumab is effective and safe for long-term usage in pediatric SEA, leading to:
Experts emphasize that careful patient selection and regular monitoring are fundamental to maximize benefits and minimize risks.
Pediatric Pulmonology
Real-World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study
Nadira Nabiyeva Çevik et al.
Comments (0)